Qrons Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York. Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain i Read MoreQrons Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Qrons Inc.
Score